Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | AKT1S1 | Q96B36 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423561 | 1.00 | DPP4 (0.36) | DPP4AOC3CYP11B2RAD51HCRTR1 | |
| SCHEMBL24253830 | 0.88 | AKT1S1 (0.36) | CYP11B2RAD51HCRTR1HCRTR2KCNH2 | |
| SCHEMBL30423907 | 0.88 | AKT1S1 (0.36) | CYP11B2RAD51HCRTR1HCRTR2KCNH2 | |
| SCHEMBL30424055 | 0.85 | RAD51 (0.31) | RAD51 | |
| SCHEMBL24253719 | 0.85 | RAD51 (0.31) | RAD51 | |
| SCHEMBL30424173 | 0.85 | RAD51 (0.31) | AOC3RAD51 | |
| SCHEMBL24253921 | 0.85 | RAD51 (0.31) | AOC3RAD51 | |
| SCHEMBL24253712 | 0.84 | KMT2A (0.41) | AOC3HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL30423539 | 0.84 | KMT2A (0.41) | AOC3HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL24253919 | 0.83 | RAD51 (0.31) | RAD51 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | DPP4 582/4885AOC3 3531/4885CYP11B2 22/4885 |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | DPP4 582/4885AOC3 3531/4885CYP11B2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.